

# Developing Robust International Principles for Responsible Innovation:

#### Insights and Implications from Ongoing OECD Work on

Neurotechnology and Society

Nina Frahm | Innovation Research, Munich Center for Technology in Society (TU Munich) David Winickoff | OECD Working Party for Biotechnology, Nanotechnology and Converging Technologies Sebastian Pfotenhauer | Innovation Research, Munich Center for Technology in Society (TU Munich)





- **1. Responsible Innovation in International Settings**
- 2. Towards OECD Principles for RI in Neurotechnology
- 3. Three Tensions and Draft Principles:
  - I. Unique concerns
  - II. Multiple (soft) governance frameworks
  - III. RI in business
- 4. Conclusion and outlook



# 1. Responsible Innovation in International Settings

- RI as an emerging imperative for STI policies
- Strong top-down institutionalization through EC
- Challenges in mainstreaming RRI across the EU
- Lead domain: Nanotechnology
- Towards a global RI framework?
  - Gaps in research and practice





14-15|01|2016 | JDE 61, 62, 63 EESC | Jacques Delors Building rue Belliard 99 | Brussels | 6<sup>th</sup> floor

#### Munich Center for Technology in Society Technische Universität München



African grant-giving

## 2. Towards OECD Principles for RI in Neurotechnology

The decade of the brain: hopes and concerns

#### TECHNOLOGY


BY DAVID GILBERT 🔰

Hacking Your Brain: Neurotech Startups Aim To Treat Depression, Alzheimer's And Parkinson's Through Headsets

ON 01/13/16 AT 9:26 AM

The ethics of experimenting

with human brain tissue






### 2.1 Neurotechnology spheres of use and implications

Neuroscience and technologies by primary function		Spheres of use		Ethical, Legal Social Implications	
Reading brain	<ul><li>Imaging</li><li>Biomarkers</li><li>modeling/mapping</li></ul>	Clinical/medical	<ul><li>Neurology/</li><li>Neurosurgery</li><li>Psychiatry</li></ul>	<ul> <li>Informed consent</li> <li>Agency, identity, autonomy</li> <li>Stigma</li> </ul>	
Intervening/ Modulating the brain	<ul> <li>Pharmaceuticals</li> <li>Neurofeedback</li> <li>Transcranial Modulation</li> <li>Deep Brain Stimulation</li> </ul>		<ul><li>Rehabilitation</li><li>Pain Medicine</li></ul>	<ul> <li>Prediction, prevention and therapeutic ga</li> <li>Safety and efficacy</li> <li>Data / brain privacy</li> <li>Off-label use, misuse and coercive use</li> </ul>	
		Occupational	<ul><li>Training</li><li>Performance</li></ul>	<ul> <li>Dual use</li> <li>Social and distributive justice and access</li> <li>Cognitive enhancement</li> </ul>	
Engineering the brain	<ul><li>Brain-computer interface</li><li>Neuroprosthetics</li></ul>	Military	<ul><li>Intelligence</li><li>Weapons</li></ul>	<ul> <li>Optimization society</li> <li>Brain determinism</li> <li>Scientific evidence</li> <li>Neuroimages in the courtroom</li> </ul>	
Derivative	<ul><li>Artificial neural networks</li><li>Al technologies</li></ul>	Public (DTC; DiY)	<ul><li>Educational</li><li>Wellness/Lifesty</li><li>le</li></ul>	<ul> <li>Neuromarketing</li> <li>Neuropolicies</li> </ul>	

# 2.2 An unprecedented momentum for NS/NT

- Worldwide rise of neurodegenerative diseases
- Rapid advancements and convergence (NBIC)
- Evolving markets for health and beyond
- Large scale national brain projects
- Collaboration and competition
- Calls for concerted action on ethical, legal, social implications



Yuste & Bargmann, Cell, 2017; OECD (BNCT) 2017.

## 2.3 BNCT Neurotechnology and Society Project

- Pool ideas, norms, and approaches for achieving more responsible innovation in neurotechnology through dialogue with stakeholders.
- Promote international deliberation, engagement, and transparency on the ethical, legal, societal, regulatory, and economic aspects upstream of neurotechnology development.
- Provide principles for responsible development, integration, and use of new and innovative neurotechnologies for health-related applications.





## 3. Three tensions

- I. Unique concerns in neurotechnology *vs*. common concerns in emerging technologies
- II. Multiple (soft) gov. frameworks vs. umbrella character of RI
- III. RI in business vs. business in society



# 3.1 Unique Concerns in Neurotechnology Innovation

- Brain privacy: special provisions of brain data vs. other health data?
- Treatment vs. enhancement: where to differentiate?
- Dual use, misuse, off-label use: what is a medical / consumer device?
- Neurotech for health and wellbeing > adaptation of bioethics guidelines
- > Special provisions on brain data
- Shared monitoring tools and oversight of risks

- adaptation of bioethics guidelines and procedures
- further research on short- and midterm ethical implications




#### 3.2 Multiple (soft) Governance Frameworks

Brain Projects	U.S. BRAIN Initiative	E.U. Human Brain Project	Brain/MINDS Japan	South Korean Brain Initiative	Australian Brain Initiative	New Zealand Brain Research
Alignment mechanisms	<ul> <li>Ethical assessment in (voluntary) multi-council working group</li> <li>DARPA NeuroELSI Panel;</li> <li>Stakeholder approach</li> </ul>	<ul> <li>Ethics and Society Subproject: Internal ethics mngmt and definition of Standard Operating Procedure</li> <li>Ethics advisory board;</li> <li>Foresight Lab and PE</li> </ul>	<ul> <li>No direct mechanism/ "in progress"</li> <li>authority within individual research institutions</li> </ul>	<ul> <li>Neuro- ethics commit- tee (recently formed)</li> </ul>	<ul> <li>Neuroethics committee</li> <li>Brain Dialogue Project (citizen juries, online discussions, participatory science)</li> </ul>	<ul> <li>Ethical guidelines;</li> <li>Maori advisory board</li> </ul>

# 3.2 Multiple (soft) Governance Frameworks

- Responsible stewardship of neurotechnology across sectors
- Institutional capacity to assess impacts on individuals AND society
- Democratic deliberation: oversight bodies and Public Engagement
- Inter- and transdisciplinary education, research and development





## 3.3 RI in Neurotechnology Business

- ELSI implications along the whole innovation process but particularly during commercialization
- Neurotechnology start-ups vs. MNEs and pharma
- PPPs and Open Science
- Business case: technology backlash, reputation
- Conceptual approach: RI in business or business in society?





Lumosity to Pay \$2 Million to Settle FTC Deceptive Advertising Charges for Its "Brain Training" Program

Company Claimed Program Would Sharpen Performance in Everyday Life and Protect Against Cognitive Decline



## 3.3 RI in Neurotechnology Business

- Design and implementation of new and/or tested strategies for responsible innovation in business
- > Transparent communication: early notification of risks in off-label use
- Clear disclosure of data use
- Cross-sectorial bodies for screening, reviewing and monitoring R&D projects and portfolios

## 4. Conclusion and Outlook

- Opportunities and challenges in mainstreaming RI
- Towards inclusive RI
  - Techno-scientific characteristics
  - Existing national governance frameworks
  - Needs and strategies of central stakeholders

- Neurotechnology Business consultation Shanghai, Sept 6-7 2018
- Deliberation across OECD countries